Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 4/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11433885 | 0.89 | KAT2B (0.49) | KAT2BLTA4HTSHRNPY5RLMNA | |
| SCHEMBL19402480 | 0.89 | KAT2B (0.49) | KAT2BLTA4HTSHRNPY5RLMNA | |
| SCHEMBL19397694 | 0.83 | KDM4E (0.47) | KAT2B | |
| SCHEMBL19397713 | 0.81 | KAT2B (0.54) | KAT2BLTA4HACACBACACA | |
| SCHEMBL19397702 | 0.80 | SLC2A1 (0.47) | KAT2BTSHR | |
| SCHEMBL17571716 | 0.80 | NPY5R (0.46) | KAT2BLTA4HNPY5RLMNAACACB | |
| SCHEMBL19402458 | 0.80 | KAT2B (0.54) | KAT2BLTA4HNPY5RACACBACACA | |
| SCHEMBL11439858 | 0.80 | KAT2B (0.48) | KAT2BLTA4HFAAHMGLLNPY5R | |
| SCHEMBL19397682 | 0.80 | KAT2B (0.52) | KAT2BLMNA | |
| SCHEMBL19397735 | 0.79 | KAT2B (0.53) | KAT2BLTA4HNPY5RACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | HDAC10, HDAC6, HDAC1 | KAT2B 41/4885LTA4H 3443/4885FAAH 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.